Product Information
LEVALBUTEROL CONC 1.25 MG/0.5 is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $5.2188 per EA under NDC 00378699393. Its NADAC has been published 355 times since Nov 28, 2013.
FDA first approved this application on Mar 20, 2009. Its Orange Book therapeutic-equivalence code is AN.
Strength
1.25 mg/.5mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378699393
Classification
Generic
Dosage Form
SOLUTION, CONCENTRATE
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
LEVALBUTEROL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078309FDA Approved
3/20/2009
TE Code
AN
On Market Since
8/28/2009
Pharmacological Classes
Price Statistics
The NADAC for LEVALBUTEROL CONC 1.25 MG/0.5 has been published 355 times since Nov 28, 2013, and over the history we have for it it has declined 3.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.2188 per EA |
|---|---|
| All-time high | $5.8349 (May 14, 2014) |
| All-time low | $3.6998 (Oct 23, 2024) |
| 52-week high | $5.2385 |
| 52-week low | $5.2188 |
| Median price | $4.7786 |
| Average price | $4.7466 |
| Largest weekly change | +26.5% (Aug 19, 2026) |
| Weeks tracked | 355 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the levalbuterol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levalbuterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta2-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVALBUTEROL CONC 1.25 MG/0.5?
The current National Average Drug Acquisition Cost (NADAC) for LEVALBUTEROL CONC 1.25 MG/0.5, manufactured by Mylan Pharmaceuticals Inc., is $5.2188 per EA (NDC 00378699393), effective Sep 30, 2026.
How has the price of LEVALBUTEROL CONC 1.25 MG/0.5 changed over time?
Over the history we have for it, the NADAC for LEVALBUTEROL CONC 1.25 MG/0.5 has declined 3.6%. It has been tracked across 355 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LEVALBUTEROL CONC 1.25 MG/0.5?
Since Nov 28, 2013, the NADAC for LEVALBUTEROL CONC 1.25 MG/0.5 has ranged from a low of $3.6998 (Oct 23, 2024) to a high of $5.8349 (May 14, 2014), with a median of $4.7786 per EA.
Are there cheaper alternatives to LEVALBUTEROL CONC 1.25 MG/0.5?
No other NADAC-published product currently shares the active ingredient and strength of LEVALBUTEROL CONC 1.25 MG/0.5 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LEVALBUTEROL CONC 1.25 MG/0.5?
LEVALBUTEROL CONC 1.25 MG/0.5 (NDC 00378699393) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.